Maintaining the Initial Clinical Response After Ketamine in Bipolar and Unipolar Depression: An Important Next-Step Challenge

Iosifescu, Dan V.

doi:10.4088/jcp.15com09904

Cited by 5 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, maintaining the initial response of ketamine infusion is an important therapeutic challenge in the psychiatric clinical practice [10]. The benefits of ketamine may be extended by repeated dosing, but ketamine infusion is resource intensive and is associated with risks, including addiction liability, dissociative symptoms, and nausea [11].…”

Section: Introductionmentioning

confidence: 99%

“…The benefits of ketamine may be extended by repeated dosing, but ketamine infusion is resource intensive and is associated with risks, including addiction liability, dissociative symptoms, and nausea [11]. Finding an optimal drug that can maintain the antidepressant effects of ketamine infusion may be clinically beneficial for patients with treatment-resistant major depression and bipolar depression [10]. D-cycloserine (DCS), a partial agonist of the glycine site of NMDA glutamate receptors, has been reported to be potentially effective for depression augmentation treatment [12,13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo–control study

Chen

Cheng

Gueorguieva

et al. 2019

Neuropsychopharmacol.

View full text Add to dashboard Cite

Increasing evidence supports a rapid antidepressant and antisuicidal effect of a single subanesthetic dose of ketamine infusion for treatment-resistant depression (TRD). Maintaining the initial clinical response after ketamine infusion in TRD is a crucial next-step challenge. D-cycloserine (DCS), a partial agonist of the glycine co-agonist of the N-methyl-D-aspartate (NMDA) glutamate receptor, is potentially effective as a depression augmentation treatment. However, whether DCS maintains the antidepressant and antisuicidal effects of ketamine infusion remains unknown. In all, 32 patients with TRD (17 with major depression and 15 with bipolar depression) who responded to ketamine infusion with an average 17-item Hamilton Depression Rating Scale (HAMD) score of 9.47 ± 4.11 at baseline were randomly divided to 6-week DCS treatment (250 mg for 2 days, 500 mg for 2 days, 750 mg for 3 days, and 1000 mg for 5 weeks) and placebo groups. Depression symptoms were rated at timepoints of dose titration and weekly. During the 6-week treatment, the total scores of HAMD did not differ between the DCS and placebo groups. The results remained consistent when stratified by disorder. A mixed model analysis indicated that the DCS group exhibited lower scores of HAMD item 3 (suicide) compared with the placebo group throughout the follow-up period (p = 0.01). A superior maintenance of the antisuicidal effect of ketamine was observed in the DCS group than in the placebo group. DCS may be therapeutically beneficial for patients with TRD who responded to ketamine infusion but have a residual suicidal risk.

show abstract

Section: Introductionmentioning

confidence: 99%